A carregar...
CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells
Natural killer (NK) cells contribute to clinical responses in patients treated with rituximab, but the rules determining NK cell responsiveness to mAb therapies are poorly defined. A deeper understanding of the mechanisms responsible for antibody-dependent cellular cytotoxicity (ADCC) could yield us...
Na minha lista:
| Publicado no: | Cancer Immunol Res |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4264658/ https://ncbi.nlm.nih.gov/pubmed/24958280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0158 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|